FDA's Semaglutide Shortage Decision Survives Appeal: What It Means for Compounders, Peptide Sellers, and Med Spas Facing Federal Exposure

The shortage argument is gone. For nearly three years anyone compounding, selling, or injecting semaglutide had a legal story to tell. The drug sat on the FDA's shortage list, and shortage status is what opened the door under the compounding provisions of the Food, Drug, and Cosmetic Act to products that would otherwise be unlawful copies of an approved drug. The FDA closed that door in February 2025. On August 27, 2026, a federal appellate court held it shut. If you source GLP-1 products outside the approved supply chain, the ground under you moved in the government's favor.

Shortage status was the condition that made compounded copies lawful. An appellate court has now reviewed the FDA's decision to end it and found both the evidence and the process adequate.

Key Takeaways

• A federal appeals court affirmed the FDA's determination that the semaglutide injection shortage resolved, leaving the agency's February 2025 order in force.
• Shortage status is what permitted compounded copies under 21 U.S.C. 353a and 353b. Without it, the compounding exception is narrow and fact-specific.
• Compounded and gray-market semaglutide now sits closer to misbranding and unapproved new drug exposure under 21 U.S.C. 331, 333, and 355.
• Prosecutors charge these matters as wire fraud and conspiracy under 18 U.S.C. 1343 and 1349, not as FDCA counts alone, which changes the sentencing math.
• The Southern and Middle Districts of Florida remain among the most active forums in the country for peptide, compounding, and med spa federal investigations.

What the Appellate Ruling Actually Settles

The FDA issued a declaratory order on February 21, 2025, finding that the shortage of semaglutide injection products had resolved. A trade association representing outsourcing facilities, joined by a custom compounding pharmacy, challenged that order in federal district court in Texas. The district court denied a preliminary injunction in April 2025 and entered summary judgment for the government that June. On August 27, 2026, the United States Court of Appeals for the Fifth Circuit affirmed.

Two holdings matter for anyone with criminal exposure. First, the court found that any error in the FDA's decision not to run a formal notice-and-comment process was harmless. The challengers had actual notice that the agency was monitoring the shortage and sent at least 34 written submissions over more than three months, and publication in the Federal Register is not required where interested parties already have actual notice. Second, the court held that the FDA reasonably relied on manufacturer supply, inventory, wholesaler, and demand data covering September 2024 through February 2025, and reasonably treated pharmacy screenshots, patient reports, surveys, and form letters as less probative than current manufacturer data.

The court did not just uphold the outcome. It upheld the FDA's evidentiary hierarchy, ranking current manufacturer supply data above pharmacy screenshots, patient reports, and form letters.

The numbers tell the story. The agency weighed roughly 310,000 compounded packages per month from outsourcing facilities and another 170,000 from pharmacy and physician compounders against a reported manufacturer capacity of 5.8 million packages per month. That is not a close call on supply, and the court did not treat it as one.

What the Government Is Building Right Now

Shortage status was never a general license. It was a condition. When it disappeared, so did the strongest good-faith argument available to sellers and clinics, and federal investigators know it. FDA Office of Criminal Investigations and DOJ have been moving from warning letters to grand jury work in this space.

The investigative pattern is consistent. Agents start with records the target never controlled: active pharmaceutical ingredient import entries, wholesaler purchase histories, payment processor data, telehealth prescribing records, and shipping manifests. They pair that with the target's own marketing. A website that says research use only while the checkout page ships vials to consumers is not a defense. It is an exhibit.

Agents build these cases from records the target never controlled. Import entries, wholesaler histories, payment processor data, and shipping manifests arrive before anyone knocks on the door.

Post-delisting conduct draws the sharpest scrutiny. Conduct during an acknowledged national shortage carries a good-faith story a jury can follow. Conduct after the spring 2025 transition deadlines, and now after an appellate court has blessed the delisting, carries a much harder one. An FDA warning letter response that ignores that shift is a wasted document.

Exposure and the Charges That Follow

The compounding provisions at 21 U.S.C. 353a for 503A pharmacies and 21 U.S.C. 353b for 503B outsourcing facilities condition the exception on the drug not being essentially a copy of a commercially available approved product. Shortage status was the pressure valve. Without it, a compounded GLP-1 product is far more likely to be an unapproved new drug under 21 U.S.C. 355 and a misbranded or adulterated article under 21 U.S.C. 331.

Penalties under 21 U.S.C. 333 start as a strict liability misdemeanor and become a felony carrying up to three years on proof of intent to defraud or mislead. Standing alone, that is survivable. Federal prosecutors rarely leave it standing alone.

The real exposure is the fraud package. Wire fraud under 18 U.S.C. 1343 carries twenty years per count, and conspiracy under 18 U.S.C. 1349 carries the same maximum as the object offense. Where a payor is billed, healthcare fraud under 18 U.S.C. 1347 adds ten years per count, and any physician compensation arrangement invites review under the Anti-Kickback Statute at 42 U.S.C. 1320a-7b. Obstruction exposure under 18 U.S.C. 1519 attaches the moment someone edits a website or deletes order records after agents make contact.

The 70-month sentence in the Paradigm Peptides case shows what that math produces when the loss figure goes unchallenged.

The Mistakes That Cost People the Case Early

Talking to agents without counsel. FDA OCI and FBI agents who appear at a clinic or a residence are there to lock in statements before anyone has documents in front of them. A false or shaded answer creates independent exposure under 18 U.S.C. 1001.

Treating a warning letter as the end of the matter. It is frequently the front end of a criminal referral, and the response you file becomes a government exhibit.

Cleaning up. Pulling product pages, rewriting disclaimers, or purging order histories after contact converts a regulatory problem into an obstruction count. Preserve everything.

Continuing to sell while under investigation. Every post-notice shipment is a fresh overt act and a fresh wire.

Waiting for the indictment. By the time charges are returned, the charging decision, the loss theory, and the target list are set. The leverage is spent.

Strategic Defense Approach

Pre-indictment defense is where these cases are won. The first move is an immediate litigation hold and an independent reconstruction of the sourcing chain: who the supplier was, what the certificates of analysis show, what licensure sat behind each prescription, and whether a good faith examination preceded each order. Build that record before the government builds its version of it.

The second move is engaging the assigned AUSA early, on terms. A presentation that separates shortage-period conduct from post-delisting conduct, documents reliance on counsel or published agency guidance, and quantifies a realistic loss figure can narrow a target list or move a client from target to subject. That does not happen after indictment.

"A presentation that separates shortage-period conduct from post-delisting conduct, documents reliance on counsel, and quantifies a realistic loss figure can move a client from target to subject. That does not happen after indictment."— Aaron M. Cohen, Principal Attorney

The cooperation question deserves a straight answer rather than a reflex. A proffer session carries real risk for an owner whose company records are already in the government's hands, and a queen for a day agreement is not immunity. The decision turns on what the government already has, where the client sits in the structure, and whether a 5K1.1 motion is realistically available.

Why the Timing Matters Now

Two clocks are running. The first is the government's. Charging decisions in these matters stay fluid for months while agents map distribution and payment flows, and that window is when a defense presentation can still change the outcome.

The second clock is legal. While the delisting was under appeal, a defense could argue the regulatory ground was unsettled. That argument is materially weaker now that an appellate court has reviewed the agency's evidence and its process and found both adequate. Anyone still operating on the theory that the shortage designation might come back is making a business decision a prosecutor will later describe as willful.

For clients here the pressure is higher. The Southern District of Florida and the Middle District of Florida have concentrated resources on healthcare and compounded-drug enforcement, and the med spa and peptide sectors in this state are dense. A South Florida healthcare fraud defense posture has to account for the fact that the same agents work these cases repeatedly and know the industry's vocabulary.

Common Questions

Under Investigation for Compounded GLP-1, Peptide, or Med Spa Conduct?

AMC Defense Law represents pharmacy owners, outsourcing facility principals, med spa operators, physicians, nurse practitioners, and platform executives in federal investigations and prosecutions involving compounded drugs, peptides, and FDA enforcement. If agents have made contact, if a grand jury subpoena or target letter has arrived, or if you are unsure whether your sourcing exposes you, a confidential consultation is the appropriate first step. The firm handles matters in Florida and nationwide.

AMC Defense Law defends pharmacies, outsourcing facilities, med spas, and prescribers in federal compounded-drug and peptide investigations in the Southern District of Florida and nationwide.

If you or your loved ones have been arrested or are under federal investigation over compounded GLP-1 products, peptides, or med spa operations, call Aaron M. Cohen, 24 hours a day to get help.

This article is for informational purposes only and does not constitute legal advice. No attorney-client relationship is formed by reading this content.